Elevated/JJ
glucocorticoid/NN
receptor/NN
concentrations/NNS
before/IN
and/CC
after/IN
glucocorticoid/NN
therapy/NN
in/IN
peripheral/JJ
mononuclear/JJ
leukocytes/NNS
of/IN
patients/NNS
with/IN
atopic/JJ
dermatitis/NN
./.

The/DT
number/NN
and/CC
affinity/NN
of/IN
glucocorticoid/NN
binding/NN
sites/NNS
in/IN
peripheral/JJ
mononuclear/JJ
leukocytes/NNS
of/IN
patients/NNS
with/IN
atopic/JJ
dermatitis/NN
(/(
AD/NN
)/)
and/CC
healthy/JJ
controls/NNS
were/VBD
determined/VBN
under/IN
baseline/NN
conditions/NNS
and/CC
after/IN
a/DT
defined/VBN
oral/JJ
glucocorticoid/NN
treatment/NN
./.
=====
Patients/NNS
with/IN
AD/NN
(/(
n/NN
=/JJ
15/CD
)/)
exhibited/VBD
significantly/RB
more/JJR
glucocorticoid/NN
receptors/NNS
(/(
GR/NN
)/)
per/IN
cell/NN
than/IN
the/DT
control/NN
group/NN
(/(
n/NN
=/JJ
22/CD
)/)
,/,
while/IN
the/DT
GR/NN
affinity/NN
did/VBD
not/RB
differ/VB
./.
=====
Methylprednisolone/NN
treatment/NN
resulted/VBD
in/IN
a/DT
significant/JJ
reduction/NN
of/IN
the/DT
GR/NN
sites/NNS
per/IN
cell/NN
in/IN
the/DT
steroid-treated/JJ
control/NN
group/NN
(/(
n/NN
=/JJ
10/CD
)/)
in/IN
contrast/NN
to/TO
the/DT
patients/NNS
./.
=====
The/DT
dissociation/NN
constant/NN
was/VBD
not/RB
affected/VBN
by/IN
methylprednisolone/JJ
treatment/NN
in/IN
either/DT
group/NN
./.
=====
In/IN
view/NN
of/IN
the/DT
therapeutic/JJ
efficiency/NN
of/IN
glucocorticoids/NNS
in/IN
AD/NN
and/CC
findings/NNS
of/IN
abnormal/JJ
cAMP/NN
and/CC
cAMP-phosphodiesterase/NN
activity/NN
,/,
the/DT
elevated/JJ
GR/NN
concentrations/NNS
in/IN
AD/NN
lend/VBP
support/NN
to/TO
the/DT
hypothesis/NN
of/IN
a/DT
compensatory/JJ
GR/NN
upregulation/NN
due/JJ
to/TO
an/DT
insufficient/JJ
action/NN
of/IN
endogenous/JJ
cortisol/NN
or/CC
to/TO
altered/JJ
cAMP-induced/JJ
GR/NN
expression/NN
./.